Menu
Light AI is addressing the health challenges of today
Our technology uses throat imaging coupled with artificial intelligence to distinguish viral versus bacterial infections. Perhaps the most important distinction between bacteria and viruses is that antibiotic drugs usually kill bacteria, but they aren’t effective against viruses.
Symptoms may be similar for bacterial and viral infections, but it is important to distinguish as the treatments vary considerably and can lead to misuse of antibiotics. Antibiotic resistance is in the top 3 global concerns for maintaining human health. This is the first new approach to diagnosis of strep throat and infectious disease since the 1980s. The gold standard of care is a throat swab culture, which can take up to two days and leads to overuse of antibiotics…
Light AI works on-demand and produces results in (near) real-time.
Symptoms may be similar for bacterial and viral infections, but it is important to distinguish as the treatments vary considerably and can lead to misuse of antibiotics. Antibiotic resistance is in the top 3 global concerns for maintaining human health. This is the first new approach to diagnosis of strep throat and infectious disease since the 1980s. The gold standard of care is a throat swab culture, which can take up to two days and leads to overuse of antibiotics…
Light AI works on-demand and produces results in (near) real-time.
❝
Even if new medicines are developed, without behaviour change, antibiotic resistance will remain a major threat ❞
WORLD HEALTH ORGANIZATION
Light AI is addressing the health challenges of today
Our technology uses throat imaging coupled with artificial intelligence to distinguish viral versus bacterial infections. Perhaps the most important distinction between bacteria and viruses is that antibiotic drugs usually kill bacteria, but they aren’t effective against viruses. Symptoms may be similar for bacterial and viral infections, but it is important to distinguish as the treatments vary considerably and can lead to misuse of antibiotics. Antibiotic resistance is in the top 3 global concerns for maintaining human health.
This is the first new approach to diagnosis of strep throat and infectious disease since the 1980s. The gold standard of care is a throat swab culture, which can take up to two days and leads to overuse of antibiotics…
Light AI can produce results in seconds.
❝
Even if new medicines are developed, without behaviour change, antibiotic resistance will remain a major threat ❞
WORLD HEALTH ORGANIZATION
The upside of testing in a post COVID-19 world
The new standard will be to screen everyone presenting with a sore throat to differentiate between bacterial and viral infections. In the United States alone this will account for over one million tests daily.
Light AI decodes infection within seconds
A person suspects or has been diagnosed with symptoms of a bacterial (such as Strep Throat) or viral infection (such as COVID-19)
For screening, live images are acquired on-demand through a smartphone or a Light AI’s device for medical settings.
The data is segmented into objects for evaluation, including only the tongue, uvula and tonsils, omitting the face.
BACKED BY ARTIFICIAL INTELLIGENCE
Thousands of images gathered from our healthcare partners are used in Machine Learning
Light AI’s Neural Engine uses advanced algorithms to identify key patterns in patient images to produce an effective probability score
- Payors and providers will need to utilize data and analytics as their competitive advantage to succeed in this new environment
- Our models have the potential to reduce the burden on clinicians and solve issues brought on by a growing baby boomer population
THE POWER OF LIGHT AI'S MACHINE LEARNING ALGORITHMS
US PTO Patent Awarded in 2022:
Australian Patent Awarded in 2022:
US2020/0107787A1
201935794
US PTO Patent Awarded in 2022
US2020/0107787A1
Australian Patent Awarded in 2022
201935794
POC RESULTS | CLINICAL PATHWAY
STATISTIC
VALUE
95% CONFIDENCE INTERVAL (CI)
Sensitivity
92.59%
75.71% to 99.09%
Specificity
100.00%
87.23% to 100.00%
Positive Likelihood Ratio
Negative Likelihood Ratio
0.07
0.02 to 0.28
Positive Predictive Value (*)
100.00%
Negative Predictive Value
93.10%
78.06% to 98.09%
Accuracy
96.30%
87.25% to 99.55%
PLANNING THE FUTURE | PRODUCT PIPELINE
Light AI is actively expanding our detection models across multiple indications to develop go-to market solutions…
- Proven ability to conduct clinical studies
- Extensive research network
- ML and CNN readiness
Group A Streptococcus
Nonspecific Viral Pharyngitis
Influenza
Respiratory Syncytial Virus (RSV)
Mononucleosis (Epstein-Barr)
Streptococcal Pneumonia
Cardiovascular
Autoimmune Disorders
Dermatology
Copyright © 2024, Light AI Inc. All rights reserved.
